Class / Patent application number | Description | Number of patent applications / Date published |
514484000 |
Ring in acid moiety
| 59 |
514489000 |
Ring in alcohol moiety
| 34 |
514480000 |
Polycyclo ring system attached by nonionic bonding
| 21 |
514479000 |
With an additional active ingredient
| 17 |
514483000 |
Plural N-C(=X)-X groups
| 13 |
514482000 |
N-C(=X)-N, N-C(=N)N, N-N, nitrogen directly bonded to oxygen by nonionic bonding or cyano containing | 5 |
20080287535 | Pesticidal diazene oxide carboxylates - Pesticidal compounds having the structural formula | 11-20-2008 |
20120178805 | PHENOLIC HYDRAZONE MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS - Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor. | 07-12-2012 |
20130090379 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug - A method of providing a patient with controlled release of tapentadol using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing tapentadol is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of tapentadol from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions. | 04-11-2013 |
20140018419 | TRI-SALT FORM OF METFORMIN - Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity. | 01-16-2014 |
20160122293 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISEASES - The invention relates to the compound of | 05-05-2016 |
Entries |
Document | Title | Date |
20080269324 | Management of Ophthalmologic Disorders, Including Macular Degeneration - A drag may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell. | 10-30-2008 |
20090088470 | ALKYL-, ALKENYL- AND ALKYNYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The invention relates to a compound of formula (I): | 04-02-2009 |
20090192219 | STABILIZATION OF IODINE-CONTAINING BIOCIDES BY MEANS OF SPECIAL AZOLE COMPOUNDS - Specific azole compounds are outstandingly suitable for stabilizing iodine-containing biocides in industrial materials, more particularly in paints based on alkyd resin. | 07-30-2009 |
20100041748 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES - The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative. | 02-18-2010 |
20100144867 | USE OF LECITHIN:RETINOL ACYL TRANSFERASE GENE PROMOTER METHYLATION IN EVALUATING THE CANCER STATE OF SUBJECT - The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed. | 06-10-2010 |
20100324134 | MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE - A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid. | 12-23-2010 |
20120178804 | NITROGEN-CONTAINING INORGANIC CARRIER MATERIALS - The invention relates to nitrogen-containing inorganic carrier materials, more particularly to inorganic carrier materials containing organically bonded nitrogen, to their preparation and also to their use for stabilizing iodine-containing compounds, and also to binder formulations comprising them and to the use thereof for protecting industrial materials. | 07-12-2012 |
20120184610 | METHODS AND FORMULATIONS FOR TREATING INEFFECTIVE OR DECREASED ESOPHAGAL MOTILITY - Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery. | 07-19-2012 |
20120232137 | Use of Bethaneciol for Treatment of Xerostomia - Bethanechol is administered topically, for the treatment of xerostomia. | 09-13-2012 |
20120277305 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES - The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative. | 11-01-2012 |
20120322868 | FOOD PRODUCTS, PREPARATION, AND THERAPEUTIC METHODS - A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the Western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a Western diet. | 12-20-2012 |
20130165508 | METHODS AND FORMULATIONS FOR TREATING INEFFECTIVE OR DECREASED ESOPHAGAL MOTILITY - Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery. | 06-27-2013 |
20140187628 | PALATABLE SUSPENDING VEHICLE FOR PHARMACEUTICAL INGREDIENTS - The invention relates to a liquid vehicle that can be used to create suspensions and/or solutions of liquid or powdered medications. The vehicle is thixotropic and has improved stability and rheologic characteristics. Vehicles of the invention include an aqueous medium and a suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages. The polysaccharide can be a starch, modified starch, or glycogen. The aqueous medium and individual components of the vehicle provide a palatable and easily ingested drug preparation. The invention also provides a vehicle containing an aqueous medium, suspending agent comprising a polysaccharide having at least 50% glucose repeating saccharide units and at least 90% alpha linkages, buffer, and artificial sweetener, the combined suspending vehicle having a pH of about 3 to about 10 and an osmolality of 300 mOmsol or less. | 07-03-2014 |
20140187629 | Use of Bethanechol for Treatment of Xerostomia - A formulation for topical administration, comprises bethanechol and a penetration enhancer. The formulation is preferably used by being maintained in the buccal cavity for a period of time prior to being swallowed. | 07-03-2014 |
20140213645 | THERMAL STABILIZATION OF IPBC BIOCIDE - A biocide, e.g. IPBC (3-iodo-2-propynl butylcarbamate), is stabilized against thermal degradation in matrix compositions which are processed at elevated temperatures, by blending the IPBC with a stabilizer additive, e.g. calcium stearate and/or a hindered phenol, alone or in combination therewith. | 07-31-2014 |
20150051279 | STABLE COMPOSITIONS OF THIABENDAZOLE AND IODINE-CONTAINING FUNGICIDES - The present invention relates to stable compositions for the fungicidal equipment of thermoplastic polymers, in particular PVC, comprising thiabendazole, at least one iodine-containing fungicide and at least one epoxide and optionally further fungicidally active compounds, and also to methods for preparing these formulations and to uses thereof for the protection of thermoplastic polymers against attack and destruction by microorganisms. Moreover, the invention relates to mold-resistant PVC materials equipped with the compositions according to the invention. | 02-19-2015 |
20150051280 | Co-Crystals of 3-Iodopropynyl Butylcarbamate - The present invention relates to biocidal agents designed to protect industrial products against microbial, bacterial, fungal and algal infections. In particular, the present invention relates to co-crystals containing 3-iodopropynyl butylcarbamate (IPBC) and to compositions containing said co-crystals which possess improved physical, chemical and workability properties compared with the use of IPBC. | 02-19-2015 |
20150087700 | NITROGEN-CONTAINING INORGANIC CARRIER MATERIALS - The invention relates to nitrogen-containing inorganic carrier materials, more particularly to inorganic carrier materials containing organically bonded nitrogen, to their preparation and also to their use for stabilizing iodine-containing compounds, and also to binder formulations comprising them and to the use thereof for protecting industrial materials. | 03-26-2015 |
20150344419 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS - The invention relates to compounds of the following formula: | 12-03-2015 |
20150366794 | USE OF BETHANECHOL FOR TREATMENT OF XEROSTOMIA - Bethanecol is administered topically, for the treatment of xerostomia. | 12-24-2015 |
20220133677 | TOPICAL COMPOSITION - Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters. | 05-05-2022 |